Mutation analysis of gastrointestinal stromal tumors: Increasing significance for risk assessment and effective targeted therapy

Virchows Archiv

Volumn 451, Issue 4, 2007, Pages 743-749

  Wardelmann, Eva ^a   Büttner, Reinhard ^a   Merkelbach Bruse, Sabine ^a   Schildhaus, Hans Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

GIST; KIT mutation; Molecular characterization; PDGFR mutation

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR;

CANCER CHEMOTHERAPY; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RISK FACTORS;

EID: 34848917796     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-007-0473-9     Document Type: Review

References (54)

1. Antonescu C, Sommer G, Sarran L, Tschernyavsky S, Riedel E, Woodruff J, Robson M, Maki R, Brennan M, Ladanyi M, DeMatteo R, Besmer P (2003) Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 9:3329-3337
2. Awasthi R, O'Neill J, Keen C, Sarsfield P, Devaraj V, Stone C, Smith M (2006) Biphasic solitary fibrous tumour: a report of two cases with epithelioid features. Virchows Arch 448:306-310
3. Blay P, Astudillo A, Buesa J, Campo E, Abad M, García- García J, Miquel R, Marco V, Sierra M, Losa R, Lacave A, Braña A, Balbín M, Freije J (2004) Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res 10:4089-4095
4. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour J, Arthur C, Joske D, Lynch K, Hughes T (2003) Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102:276-283
5. Buchdunger E, Cioffi C, Law N, Stover D, Ohno-Jones S, Druker B, Lydon N (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139-145
6. Corless C, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, Heinrich M (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23:5357-5364
7. Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen H, Roesel J, Hagemeijer A, van Osteroom A, Marynen P (2005) Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against Imatinib-resistant mutants. Gastroenterology 128:270-279
8. Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, Dimitrijevic S, Sciot R, Stul M, Vranck H, Scurr M, Hagemeijer A, van Glabbeke M, van Osteroom A (2004) Use of c-kit/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40:689-695
9. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom A, Blay J, Leyvraz S, Stul M, Casali P, Zalcberg J, Verweij J, Van Glabbeke M, Hagemeijer A, Judson I, on behalf of the EORTC Soft Tissue and Bone Sarcoma Group TISGatAGTG (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42:1093-1103
10. DeMatteo R, Heinrich MC, El-Rifai W, Demetri GD (2002) Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 33:466-477
11. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors of survival. Ann Surg 231:51-58
12. Demetri GD (2001) Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol 28:19-26
13. Demetri GD, Desai J, Fletcher J, Morgan J, Fletcher C, Kazanovicz A, Van den Abbeele AD, Baum C, Maki R, Heinrich MC (2004) SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). 2004 ASCO Annual Meeting: Abstract No. 3001
14. Fletcher CD, Berman J, Corless CL, Gorstein F, Lasota J, Longley B, Miettinen M, O'Leary T, Remotti H, Rubin BP, Shmookler B, Sobin L, Weiss S (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459-465
15. Friedrichs N, Testi M, Moiraghi L, Modena P, Paggen E, Plötner A, Wiechmann V, Mantovani-Löffler L, Merkelbach-Bruse S, Buettner R, Wardelmann E (2005) Clear cell sarcoma-like tumour with giant cells in the small bowel-further evidence for a new tumor entity? Int J Surg Pathol 13:313-318
16. Gorre M, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P, Sawyers C (2001) Clinical resistance to STI-571 cancer therapy caused by bcr-abl gene mutation or amplification. Science 293:876-880
17. Heinrich MC, Corless CL, Demetri GD, Blancke CD, von Mehren M, Joensuu H, Mc Greevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumors. J Clin Oncol 21:4342-4349
18. Heinrich MC, Corless CL, Duensing A, Mc Greevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CDM, Fletcher JA (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710
19. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood 96:925-932
20. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580
21. Hirota S, Nishida T, Isozaki K, Taniguchi M, Nakamura J, Okazaki T, Kitamura Y (2001) Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 193:505-510
22. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, Kitamura Y (2003) Gain-of-function mutations in platelet-derived growth factor receptor a gene in gastrointestinal stromal tumors. Gastroenterology 125:660-667
23. Hohenberger P, Reichardt P, Gebauer B, Wardelmann E (2004) Gastro-intestinal stromal tumors (GIST)-current aspects of surgical management. DMW 129:1817-1820
24. Kim K, Kang D, Moon W, Park J, Park C, Sohn J, Jeong J, Cho M, Jin S, Choi J, Kang D (2006) PKCtheta expression in gastrointestinal stromal tumor. Mod Pathol 19:1480-1486
25. Kindblom LG, Remotti HE, Aldenborg F, Meis Kindblom JM (1998) Gastrointestinal pacemaker cell tumor (GIPACT)-gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259-1269
26. Kinoshita K, Isozaki K, Hirota S, Nishida T, Chen H, Nakahara M, Nagasawa Y, Ohashi T, Shinomura Y, Kitamura Y, Matsumura Y (2003) c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors. J Gastroenterol Hepatol 18:147
27. Lasota J, Dansonka-Mieszkowska A, Sobin L, Miettinen M (2004) A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 84:874-883
28. Lasota J, Dansonka-Mieszkowska A, Stachura T, Schneider-Stock R, Kallajoki M, Steigen S, Sarlomo-Rikala M, Boltze C, Kordek R, Roessner A, Stachura J, Miettinen M (2003) Gastrointestinal stromal tumors with internal tandem duplications in 3′ end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol 16:1257-1264
29. Lasota J, Stachura J, Miettinen M (2006) GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest 86:94-100
30. Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R, Nassar A, Sobin LH, Miettinen M (2000) Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. Am J Pathol 157:1091-1095
31. Ma Y, Cunningham ME, Wang X, Ghosh I, Regan L, Longley BJ (1999) Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region. J Biol Chem 19:13399-13402
32. Martin J, Poveda A, Llombart-Bosch A, Ramos R, López-Guerrero J, Garcia del Muro J, Maurel J, Calabuig S, Gutierrez A, González de Sande J, Martinez J, De Juan A, Lainez N, Losa F, Alija V, Escudero P, Casado A, Garcia P, Blanco R, Buesa J (2005) Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 23:6190-6198
33. Medeiros F, Corless CL, Duensing A, Hornick J, Oliveira A, Heinrich MC, Fletcher JA, Fletcher CD (2004) KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 28:889-894
34. Miettinen M, El-Rifai W, Sobin LH, Lasota J (2002) Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 33:478-483
35. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23:70-83
36. Miettinen M, Monihan JM, Sarlomo-Rikala M, Kovatich AJ, Carr NJ, Emory TS, Sobin LH (1999) Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathological and immunohistochemical study of 26 cases. Am J Surg Pathol 23:1109-1118
37. Miettinen M, Sarlomo-Rikala M, Lasota J (1999) Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 30:1213-1220
38. Miettinen M, Sobin L, Lasota J (2005) Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long term follow up. Am J Surg Pathol 29:52-68
39. Miettinen M, Sobin LH, Maklouf H, Lasota J (2006) Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30:477-489
40. Miettinen M, Sobin LH, Sarlomo-Rikala M (2000) Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117. Mod Pathol 13:1134-1142
41. Pauls K, Merkelbach-Bruse S, Thal D, Büttner R, Wardelmann E (2004) PDGFR and c kit mutated gastrointestinal stromal tumors (GISTs) are characterized by distinctive histological and immunohistochemical features. Histopathology 46:166-175
42. Robinson TL, Sircar K, Hewlett BR, Chorneyko K, Riddell RH, Huizinga JD (2000) Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal. Am J Pathol 156:1157-1163
43. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118-8121
44. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M (1998) CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 11:728-734
45. Taminelli L, Zaman K, Gengler C, Peloponissios N, Bouzourene H, Coindre J-M, Hostein I, Guillou L (2005) Primary clear cell sarcoma of the ileum: an uncommon and misleading site. Virchows Arch 447:772-777
46. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD (2001) STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20:5054-5058
47. Vanderwinden JM, Rumessen JJ, De Laet MH, Vanderhaeghen JJ, Schiffmann SN (1999) CD34+ cells in human intestine are fibroblasts adjacent to, but distinct from, interstitial cells of Cajal. Lab Invest 79:59-65
48. Verweij J, Casali P, Zalcberg J, Le Cesne A, Reichardt P, Blay J, Issels R, van Osteroom A, Hogendoorn P, Van Glabbeke M, Bertulli R, Judson I (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1101-1102
49. Wardelmann E, Hrychyk A, Merkelbach-Bruse S, Pauls K, Goldstein J, Hohenberger P, Losen I, Manegold C, Büttner R, Pietsch T (2004) Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diagn 6:197-204
50. Wardelmann E, Losen I, Hans V, Neidt I, Speidel N, Bierhoff E, Heinicke T, Pietsch T, Büttner R, Merkelbach-Bruse S (2003) Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 106:887-895
51. Wardelmann E, Merkelbach-Bruse S, Pauls K, Thomas N, Schildhaus H, Heinicke T, Speidel N, Pietsch T, Buettner R, Pink D, Reichardt P, Hohenberger P (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12:1743-1749
52. Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, Büttner R, Bihl H, Leutner C, Heinicke T, Hohenberger P (2005) Acquired resistance to imatinib in gastrointestinal stromal tumors caused by multiple KIT mutations. Lancet Oncology 6:249-251
53. West R, Corless C, Chen X, Rubin B, Subramanian S, Montgomery K, Zhu S, Ball C, Nielsen T, Patel R, Goldblum J, Brown P, Heinrich M, van de Rijn M (2004) The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 165:107-113
54. Zambrano E, Reyes-Mugica M, Franchi A, Rosai J (2003) An osteoclast-rich tumor of the gastrointestinal tract with features resembling clear cell sarcoma of soft parts: reports of 6 cases of a GIST simulator. Int J Surg Pathol 11:75-81